Invention Grant
- Patent Title: Macrocyclic proline derived HCV serine protease inhibitors
- Patent Title (中): 大环脯氨酸衍生的HCV丝氨酸蛋白酶抑制剂
-
Application No.: US13237120Application Date: 2011-09-20
-
Publication No.: US08648037B2Publication Date: 2014-02-11
- Inventor: Yat Sun Or , Jun Ma , Guoqiang Wang , Jiang Long , Bin Wang
- Applicant: Yat Sun Or , Jun Ma , Guoqiang Wang , Jiang Long , Bin Wang
- Applicant Address: US MA Watertown
- Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A01N37/18
Abstract:
The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Public/Granted literature
- US20120070416A1 Macrocyclic Proline Derived HCV Serine Protease Inhibitors Public/Granted day:2012-03-22
Information query
IPC分类:
